We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
- Authors
Decaudin, Didier; Mounier, Nicolas; Tilly, Hervé; Ribrag, Vincent; Ghesquières, Hervé; Bouabdallah, Krimo; Morschhauser, Franck; Coiffier, Bertrand; Le Gouill, Steven; Bologna, Serge; Delarue, Richard; Huynh, Anne; Bosly, André; Brière, Josette; Gisselbrecht, Christian
- Abstract
This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas.
- Publication
Clinical lymphoma, myeloma & leukemia, 2011, Vol 11, Issue 2, p212
- ISSN
2152-2669
- Publication type
Journal Article
- DOI
10.1016/j.clml.2011.03.007